Insider Trading Alert - JASN, HFWA And KERX Traded By Insiders
Yesterday, Nov. 5, 2015, 68 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $5.04 to $15,303,456.72.
Highlighted Stocks Traded by Insiders:
Jason Industries (JASN) - FREE Research Report
Scopus Partners, L.P., who is 10% Owner at Jason Industries, sold 3,673 shares at $4.07 on Nov. 5, 2015. Following this transaction, the 10% Owner owned 113,562 shares meaning that the stake was reduced by 3.13% with the 3,673-share transaction.
Scopus Vista Partners, L.P., who is 10% Owner at Jason Industries, sold 7 shares at $4.07 on Nov. 5, 2015. Following this transaction, the 10% Owner owned 87,827 shares meaning that the stake was reduced by 0.01% with the 7-share transaction.
Scopus Fund Ltd., who is 10% Owner at Jason Industries, sold 13,399 shares at $4.07 on Nov. 5, 2015. Following this transaction, the 10% Owner owned 435,016 shares meaning that the stake was reduced by 2.99% with the 13,399-share transaction.
Scopus Vista Fund Ltd., who is 10% Owner at Jason Industries, sold 7 shares at $4.07 on Nov. 5, 2015. Following this transaction, the 10% Owner owned 26,253 shares meaning that the stake was reduced by 0.03% with the 7-share transaction.
Scopus Partners Ii, L.P., who is 10% Owner at Jason Industries, sold 26,450 shares at $4.07 on Nov. 5, 2015. Following this transaction, the 10% Owner owned 494,006 shares meaning that the stake was reduced by 5.08% with the 26,450-share transaction.
The shares most recently traded at $3.85, down $0.22, or 5.59% since the insider transaction. Historical insider transactions for Jason Industries go as follows:
- 4-Week # shares bought: 1,600
- 4-Week # shares sold: 26,600
- 12-Week # shares bought: 96,532
- 12-Week # shares sold: 26,600
- 24-Week # shares bought: 179,895
- 24-Week # shares sold: 26,600
The average volume for Jason Industries has been 36,200 shares per day over the past 30 days. Jason Industries has a market cap of $88.6 million and is part of the industrial goods sector and industrial industry. Shares are down 59.44% year-to-date as of the close of trading on Thursday.
Jason Industries, Inc., together with its subsidiaries, engages in the manufacture of seating, finishing, acoustics, and components in the United States and internationally. Currently, there are 2 analysts who rate Jason Industries a buy, no analysts rate it a sell, and none rate it a hold.
Exclusive Offer: Get the latest Stock Analysis on JASN - FREE
rates Jason Industries as a
. The company's weaknesses can be seen in multiple areas, such as its generally disappointing historical performance in the stock itself, generally high debt management risk and poor profit margins. Get the full
Jason Industries Ratings Report
from
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Heritage Financial (HFWA) - FREE Research Report
Hinson Donald, who is EVPand Chief Financial Officer at Heritage Financial, sold 1,000 shares at $19.20 on Nov. 5, 2015. Following this transaction, the EVPand Chief Financial Officer owned 35,716 shares meaning that the stake was reduced by 2.72% with the 1,000-share transaction.
The shares most recently traded at $19.35, up $0.15, or 0.77% since the insider transaction. Historical insider transactions for Heritage Financial go as follows:
- 4-Week # shares bought: 169
- 4-Week # shares sold: 1,000
- 12-Week # shares bought: 169
- 12-Week # shares sold: 3,000
- 24-Week # shares bought: 169
- 24-Week # shares sold: 3,000
The average volume for Heritage Financial has been 107,100 shares per day over the past 30 days. Heritage Financial has a market cap of $573.9 million and is part of the financial sector and banking industry. Shares are up 9.06% year-to-date as of the close of trading on Thursday.
Heritage Financial Corporation operates as the bank holding company for Heritage Bank that provides various financial services to small businesses and general public. The stock currently has a dividend yield of 2.3%. The company has a P/E ratio of 16.2. Currently, there is 1 analyst who rates Heritage Financial a buy, no analysts rate it a sell, and 4 rate it a hold.
Exclusive Offer: Get the latest Stock Analysis on HFWA - FREE
rates Heritage Financial as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, compelling growth in net income, expanding profit margins and solid stock price performance. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full
Heritage Financial Ratings Report
from
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Keryx Biopharmaceuticals (KERX) - FREE Research Report
Holmes Scott A, who is Chief Financial Officer at Keryx Biopharmaceuticals, bought 5,000 shares at $5.33 on Nov. 5, 2015. Following this transaction, the Chief Financial Officer owned 59,742 shares meaning that the stake was boosted by 9.13% with the 5,000-share transaction.
The shares most recently traded at $5.03, down $0.30, or 5.88% since the insider transaction. Historical insider transactions for Keryx Biopharmaceuticals go as follows:
- 4-Week # shares bought: 5,000
- 4-Week # shares sold: 1,011
- 12-Week # shares bought: 14,984
- 12-Week # shares sold: 1,011
- 24-Week # shares bought: 24,984
- 24-Week # shares sold: 8,481
The average volume for Keryx Biopharmaceuticals has been 2.6 million shares per day over the past 30 days. Keryx Biopharmaceuticals has a market cap of $567.0 million and is part of the health care sector and drugs industry. Shares are down 64.24% year-to-date as of the close of trading on Thursday.
Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on providing therapies for patients with renal disease in the United States. Currently, there are 5 analysts who rate Keryx Biopharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.
Exclusive Offer: Get the latest Stock Analysis on KERX - FREE
rates Keryx Biopharmaceuticals as a
. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, poor profit margins and generally disappointing historical performance in the stock itself. Get the full
Keryx Biopharmaceuticals Ratings Report
from
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.